BridgeBio Pharma, Inc. Earnings Recaps
Q1 2026
May 9, 2026
Shares declined modestly by 1.0% following a Q1 report that showed ongoing commercial momentum for Attruby but lacked near-term clinical catalysts or definitive upside in competitive positioning, reflecting investor caution amid a cautious outlook.
Key takeaways
- Attruby net product revenue reached $180.6 million in the U.S., up 24% sequentially and 392% year-over-year, supporting its trajectory toward blockbuster status in 2026.
- The company highlighted progress in clinical differentiation, with emerging real-world evidence suggesting Attruby’s superiority over Pfizer’s tafamidis in certain outcomes, including a 43% reduction in diuretic intensification.
- Total new patient starts in the category exceeded 6,100 this quarter, with BridgeBio positioned as the clear second by volume, though Pfizer maintains the front-line lead.
- Near-term outlook remains cautious with no major clinical catalysts expected, although multiple first-in-class or best-in-class launches are in preparation.
- Management announced an immediate share buyback program aiming to capture long-term value amid the stock trading well below intrinsic valuation.